Market accessOfficial

SÚKL publishes Czech list of drug prices and reimbursements effective 1 November 2026

🇨🇿 SÚKL · Tue 27 Oct 2026

The Czech medicines authority has released the monthly reimbursement list, with maximum prices, reimbursement levels, indication restrictions and change files for products paid by public health insurance.

The State Institute for Drug Control (SÚKL) published the List of Prices and Reimbursements of Medicinal Products (Seznam cen a úhrad LP) on 27 October 2026. It takes effect on 1 November 2026 and is issued under Section 39n(1) of Act No. 48/1997 Coll. on public health insurance.

According to SÚKL, the list is issued as of the first day of each calendar month. It sets out all medicines reimbursed from public health insurance for which the Institute decides on reimbursement. For each it gives the maximum or notified manufacturer price, the amount and conditions of reimbursement, the highest possible reimbursement for the end consumer, and the patient co-payment up to the countable limit.

The list also covers the basic reimbursement amounts for reference groups, with the reasoning for how they were set and a full list of the products in each group. It further includes maximum prices for medicines where SÚKL decides only on price, again with the full product list and the rationale.

SÚKL states that the list reflects a 12% VAT rate and Ministry of Health Price Decision No. 1/2026/OLZP of 24 October 2025 on the regulation of prices of medicinal products and foods for special medical purposes.

Alongside the main list, SÚKL has posted spreadsheets of changes in reimbursements, maximum manufacturer prices, countable co-payments and indication restrictions. It also provides full and incremental or decremental files against the 1 October 2026 list, a separate list of products used only in inpatient care, code tables and data-interface documentation in version 21.

What it means for your team

  • Pricing and reimbursement teams should check the 1 November 2026 maximum prices, reimbursement amounts and co-payments for their Czech portfolios.
  • Reimbursement changes and amended indication restrictions are published in separate files, which allow teams to isolate what has moved since the October list.
  • Teams that load SÚKL data into internal systems should note that the files use data interface version 21 and come with updated code tables.
  • Reference-group base reimbursements and their stated rationale may matter for products in groups where reimbursement levels have changed.

Official source: SÚKL ↗

Article written by VigiEye from the official source (SÚKL). AI-assisted; check the source before acting.

More Market access All →